Saturn V Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Saturn V Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-524,811	Closed	-$20.2M	–	24
2023 Q2	$20.2M	Buy	524,811 +17,993	+4%	+$462K	11.18%	1
2023 Q1	$11.7M	Buy	506,818 +83,641	+20%	+$1.99M	8.76%	3
2022 Q4	$6.73M	Buy	+423,177	New	+$9.37M	5.58%	10

Saturn V Capital Management's KDNY Position: Q3 2023 in Review

Saturn V Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 524,811 shares — an estimated $20.2M sold.

Saturn V Capital Management first reported a position in KDNY in Q4 2022 and held it in 3 quarters. The position peaked at $20.2M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Saturn V Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Saturn V Capital Management sold 524,811 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $20.2M.
Saturn V Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
Saturn V Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $20.2M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Saturn V Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.